Pharmaron Beijing Co Ltd (300759)
Shenzhen Stock Exchange · China · prices in CNY · close of 23 Oct 2026
Key indicators
| Last close | CNY 38.02 |
|---|---|
| 52-week range | 21.01 – 53.57 |
| Return, 1 month / 3 months | −15.5% / −2.5% |
| Return, 1 year / 3 years | +21.7% / +34.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 40 |
| Volatility (1 year) | 47.5% |
| Worst drawdown (1 year) | -36.2% |
| Average daily value traded | 2,547.89M CNY |
| Dividend yield | 0.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Pharmaron Beijing is a contract research organisation that supports pharmaceutical and biotechnology companies in discovering and developing new medicines. It provides laboratory research services such as medicinal chemistry, biology and preclinical safety testing, along with development and manufacturing support for drug candidates. The company is based in Beijing, China, and runs laboratory and production sites in China and overseas, serving clients who outsource parts of their research and development work.
The shares are listed on the Shenzhen Stock Exchange in China under the code 300759, and the price on this page is in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Pharmaron Beijing Co Ltd (300759) trades on the Shenzhen Stock Exchange in China. It last closed at CNY 38.02 on 23 October 2026.
Its price-based Market X-Ray is 78 out of 100 (a strong price profile), ranking 73 of 2,821 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 21.7% and over the last three months it fell 2.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shenzhen Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 93 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 15.6% | ||
| From 52-week high | -25.7% | ||
| Momentum | 74 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -2.5% | ||
| 6-month return | 29.2% | ||
| 12-month return, skipping the last month | 44.1% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 47.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -36.2% | ||
| Liquidity | 98 · Strong | Trades actively. | |
| Average daily value traded | 2,547.89M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | 48 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.5% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.5% |
|---|---|
| 1 month | −15.5% |
| 3 months | −2.5% |
| 6 months | +29.2% |
| 1 year | +21.7% |
| 3 years | +34.1% |
| 5 years | −51.7% |
Signals
| 50-day / 200-day average | 43.60 / 32.90 |
|---|---|
| Golden / death cross (60 days) | Golden, 52 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.43 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 7 Jul 2026 | CNY 0.2000 |
| 4 Jul 2025 | CNY 0.2000 |
| 27 Jun 2024 | CNY 0.2000 |
| 27 Jul 2023 | CNY 0.4500 |
| 14 Jun 2022 | CNY 0.6750 |
| 30 Jun 2021 | CNY 0.3000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shenzhen Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.